Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/celltrion-inc" target="_blank" data-smartkarma-citation="entities:991:1" rel="noopener">Celltrion Inc (068270 KS)</a> achieved 31% YoY revenue growth to KRW882B in 3Q24, driven by the rapid growth of new products such as Remsima SC, Yuflyma, and Vegzelma.</li>
<li>The company is maintaining 2024 sales guidance of KRW3.5T (up 60% YoY), which indicates sequentially improved quarterly sales in 4Q24. Margin improvement is expected to continue.</li>
<li>In August, Celltrion received EU approval for Steqeyma, biosimilar for autoimmune disease treatment Stelara. Celltrion aims to commercialize 22 biosimilars by 2030, thereby targeting a pipeline market size of $182B.</li>
</ul>



Celltrion Inc (068270 KS) achieved 31% YoY revenue growth to KRW882B in 3Q24, driven by the rapid growth of new products such as Remsima SC, Yuflyma, and Vegzelma.
The company is maintaining 2024 sales guidance of KRW3.5T (up 60% YoY), which indicates sequentially improved quarterly sales in 4Q24. Margin improvement is expected to continue.
In August, Celltrion received EU approval for Steqeyma, biosimilar for autoimmune disease treatment Stelara. Celltrion aims to commercialize 22 biosimilars by 2030, thereby targeting a pipeline market size of $182B.


Celltrion Inc (068270 KS): Record High Sales in 3Q; Pipeline Progress Entails Long-Term Growth

Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Korea/Asia, Events, IPOs

Douglas Research Advisory

Equity Capital Markets

<ul>
<li><strong>This is our 10th "Annual Edition of the Major Korean IPOs Pipeline Preview" at Smartkarma.</strong></li>
<li>This insight will feature 50 of the biggest potential IPOs in Korea in 2025.</li>
<li>These 50 IPOs in Korea are likely to represent more than 80% of all capital raised through IPOs in Korea next year.</li>
</ul>


This is our 10th "Annual Edition of the Major Korean IPOs Pipeline Preview" at Smartkarma.
This insight will feature 50 of the biggest potential IPOs in Korea in 2025.
These 50 IPOs in Korea are likely to represent more than 80% of all capital raised through IPOs in Korea next year.


2025 ("Year of the Snake") Major IPOs Pipeline in Korea

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyzed the changes in short interest of KRX stocks as of Nov 29th which has an aggregated short interest worth USD4.2bn.</li>
<li>We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.</li>
<li>We highlight short interest changes in Korea Zinc, JYP, SK Hynix.</li>
</ul>


We analyzed the changes in short interest of KRX stocks as of Nov 29th which has an aggregated short interest worth USD4.2bn.
We tabulate league table for top short by value and short as multiple of ADT, as well as weekly increases &amp; decreases in short value, short as multiple of ADT.
We highlight short interest changes in Korea Zinc, JYP, SK Hynix.


KRX Short Interest Weekly (Nov 29th):Korea Zinc, JYP, SK Hynix

CEO, A. Stotz Investment Research

Dr. Andrew Stotz, CFA

Quantamental Investing to beat Benchmarks

A. Stotz Investment Research

We pick stocks. We construct portfolios. All our effort is focused on how to better pick stocks and construct portfolios. We serve fund management companies, family offices, and high net worth individuals.

Thematic (Sector/Industry)

<ul>
<li>We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology</li>
<li>Portfolio changes: Five stock remains, nine stocks added into portfolio</li>
<li>Since its inception, it has generated a before-fee total return of 193% versus the MSCI Asia ex Japan of 89%</li>
</ul>


We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology
Portfolio changes: Five stock remains, nine stocks added into portfolio
Since its inception, it has generated a before-fee total return of 193% versus the MSCI Asia ex Japan of 89%


Tracking developments across tech supply chains, Tech Supply Chain Tracker

Tech Supply Chain Tracker

Tracking developments across tech supply chains

<ul><li>India's PC market shows growth in 3Q24, indicating signs of recovery in the industry after a challenging period.</li><li>Taiwan's aerospace industry experiences a surge in ambitions amidst global security worries, highlighting the region's competitive edge.</li><li>Samsung makes changes in leadership with new foundry CTO appointment, signaling a strategic shift in the company's direction.</li></ul>

India's PC market shows growth in 3Q24, indicating signs of recovery in the industry after a challenging period.Taiwan's aerospace industry experiences a surge in ambitions amidst global security worries, highlighting the region's competitive edge.Samsung makes changes in leadership with new foundry CTO appointment, signaling a strategic shift in the company's direction.

Tech Supply Chain Tracker (28-Nov-2024): India PC market recovering, slight shipment growth in 3Q24.

South Korea

Samsung Biologics Co.,Ltd. manufactures bio-healthcare products. The Company develops, refines, and distributes biopharmaceutical products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Samsung Biologics (207940 KS)

Celltrion Inc (068270 KS): Record High Sales in 3Q; Pipeline Progress Entails Long-Term Growth

Celltrion has announced dividend of KRW750 per share and one bonus shares for every 20 shares held. The record date for dividend payment and bonus...

Tina Banerjee

2025 ("Year of the Snake") Major IPOs Pipeline in Korea

This is our 10th "Annual Edition of the Major Korean IPOs Pipeline Preview" at Smartkarma. This insight will feature 50 of the biggest potential...

Douglas Kim

KRX Short Interest Weekly (Nov 29th):Korea Zinc, JYP, SK Hynix

We analyzed KRX short interest report for the past week and highlighted short interest changes in Korea Zinc, JYP, SK Hynix.

Ke Yan, CFA, FRM

The Stocks to Own in Asia – Vol. 47

We highlight 14 stocks in Asia that look interesting to us based on our FVMR methodology. Portfolio changes: Five stock remains, nine stocks added.

A. Stotz Investment Research

Tech Supply Chain Tracker (28-Nov-2024): India PC market recovering, slight shipment growth in 3Q24.

India sees slight growth in PC shipments, Taiwan's aerospace sector thrives, Samsung appoints new CTO, Taiwan and Germany collaborate on AI license...

Tech Supply Chain Tracker

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)